National Tribune
Wednesday, 18 November 2026
Health

FGF19-FGFR4 pathway has dual roles in liver health and cancer

A review published in Genes & Diseases examines a pathway that can both protect the liver and contribute to its destruction. Researchers at Tongji Hospital, Huazhong University of Science and Technology, describe how FGF19-FGFR4 signaling regulates metabolism and tissue repair, while abnormal activation can promote liver cancer and complicate treatment.

The pathway connects signals from the intestine with responses in the liver. Fibroblast growth factor 19, or FGF19, binds to its receptor FGFR4 with help from a protein called β-Klotho. This interaction helps control bile acid production, glucose handling, and fat metabolism, maintaining processes essential for liver health.

Bile acids support digestion, but excessive accumulation can damage tissues. FGF19 acts as part of a feedback system that limits their production. The review also examines the pathway's involvement in liver regeneration and its changing roles in metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and conditions involving impaired bile flow.

These protective functions have encouraged research into therapies that mimic FGF19. The review describes clinical studies of aldafermin, an engineered FGF19 analog, reporting reductions in liver fat and improvements in some measures of liver disease and fibrosis. However, diarrhea and potential cancer-promoting effects observed in certain animal models highlight the need for safety assessment.

In hepatocellular carcinoma, the most common primary liver cancer, excessive FGF19-FGFR4 activity can support tumor cell survival, spread, immune suppression, and resistance to treatment. This creates a different therapeutic goal: blocking the pathway rather than enhancing its metabolic effects.

Selective FGFR4 inhibitors offer one potential approach. In an early clinical trial summarised in the review, fisogatinib produced responses in 17% of patients with FGF19-positive tumors, compared with none in the FGF19-negative group. The finding supports investigating tumor FGF19 expression as a marker for selecting patients who might benefit.

The review also explores combinations with immunotherapy and other anticancer agents. Experimental studies suggest these strategies could strengthen tumor control, although clinical evidence remains limited. Acquired mutations in FGFR4 can cause drug resistance, reinforcing the need for inhibitors and better treatment selection.

A central challenge is separating metabolic benefits from signals that stimulate unwanted cell growth. Future research must clarify how disease stage, tissue context, and interactions with other pathways determine whether FGF19-FGFR4 activity is protective or harmful.

Source:

Journal reference:

Wu, Z., et al. (2026) The role of FGF19-FGFR4 signaling pathway in liver health and disease: Guardian or destroyer. Genes & Diseases. DOI: 10.1016/j.gendis.2025.101989. https://www.sciencedirect.com/science/article/pii/S2352304225004787?via%3Dihub

Originally reported by News-Medical.